Market Overview:

The global antiglaucoma eye drops market size was significantly robust in 2020 and is expected to register a steady revenue CAGR over the forecast period. Key factors driving market revenue growth are ever-increasing usage of Xalatan, Lumigan, and Travatan drugs to lower eye pressure. The pharmaceutical sector manufactures drugs that can be used to diagnose, remedy, cure, or fight infections. Prescription medications are subordinate to a plethora of rules and regulations concerning copyrighting, testing, safety, effectiveness, and advertising. Prescription medications containing Active Pharmaceutical Ingredients (API) and excipients are manufactured by antiglaucoma drug manufacturers. Glaucoma is a group of eye conditions that cause harm to the eye's optic nerve, thereby resulting in vision loss and impaired vision.

Major Factors Driving Growth Of The Global Antiglaucoma Eye Drops Market:

Revenue growth of the global antiglaucoma eye drops market is being fueled by rising interest of patients on the treatment of glaucoma and development of a new class of compound known as Rho-kinase inhibitors by pharmaceutical companies. The Rho-kinase pathway is essential for cellular functions such as vascular smooth muscle cell contraction, actin cytoskeleton organization, cell attachment and cell migration, and gene function. Rho-kinase inhibitors vary from commonly used prostaglandin analogues in that, these aim for trabecular meshwork outflow instead of uveoscleral discharge. Rho-kinase inhibitors have been shown to reduce intraocular pressure by 25% to 30% with a spectrum of activity of 10 to 12 hours, in order to be more effective than earlier generations of drugs for this circumstance. These factors are anticipated to drive market revenue growth in the near future.

Factors Restraining Growth Of The Global Antiglaucoma Eye Drops Market:

The global antiglaucoma eye drops market growth is substantially hampered by various unfavorable factors. In the United States and Europe, anti-glaucoma drugs are facing patent expiration. For instance, travoprost and bimatoprost, which can be used to treat the condition, will lose patents soon. This will result in the introduction of generic versions of drugs that are less expensive than branded ones, thereby lessening expansion of the global market. COVID-19 also has the potential to negatively impact the global economy in three ways: directly affecting production and demand, causing supply chain and market disruption, and having a financial effect on firms and currency sectors.

Opportunities For Players Operating In The Global Antiglaucoma Eye Drops Market:

The global antiglaucoma eye drops market is projected to expand rapidly during the forecast period. Increasing emphasis on the development of rho kinase inhibitors for Glaucoma Treatment, advancement of adjuvant therapy, and development of Artificial Intelligence (AI) are expected to create growth opportunities for new entrants and well-established companies operating in the market. In addition, many key players are striving to expand businesses through strategic partnerships and collaborative efforts, as well as concentrating on the advancement and release of new drugs.

Global Antiglaucoma Eye Drops Market Revenue Led By Product Type Segment:

The market for antiglaucoma eye drops is segmented into alpha agonist, beta blockers, prostaglandin analogs, combined medication, and others. Over the forecast period, prostaglandin analogues segment is expected to grow at a faster rate, owing to increasing prevalence of open-angle glaucoma. Alpha agonist is also expected to be the fastest-growing segment in the antiglaucoma eye drops market over the forecast period as this type of drugs cause less side-effects than others.

Global Antiglaucoma Eye Drops Market Leading Disease Condition Segment:

The global antiglaucoma eye drops market is segmented into open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, and others, in terms of disease condition. Open-angle glaucoma was the largest segment of the antiglaucoma drugs market in 2020. In the future, angle-closure glaucoma is expected to be the fastest-growing segment in the antiglaucoma eye drops market by disease condition. Increasing geriatric population is a major driver of this segment’s growth.

North America Accounts For Largest Revenue Share In Global Light Controls Market:

The North America market for antiglaucoma eye drops is the largest and is estimated to remain so throughout the forecast period. Glaucoma incidence rises with age, and as the world's largest geriatric population is growing, governments of developed countries in this region are trying to launch projects to make people aware about glaucoma and similar other eye disorders. For instance, the Centers for Disease Control and Prevention (CDC) in the United States launched the Vision Health initiative to prevent eye disorders such as glaucoma and to improve the overall eye health.

Asia Pacific Continues To Lead In Terms Of Revenue CAGR:

In the antiglaucoma eye drops market, Asia Pacific is mainly dominated by China, South Korea, Japan, and India. Access to advanced medical care is bound to enhance in developing countries, thereby bolstering the market for anti-glaucoma eye drops. The main reason behind the efficiency of state-of-the-art healthcare access in many developing countries, including India, China, and some Latin American countries, is the successful implementation of various government healthcare plans. Many countries, including Russia and Brazil, are working to improve medical systems, which will ultimately steer the anti-glaucoma eye drops market.

Major Companies Profiled In The Report:

  • Walgreens
  • Meda Pharmaceuticals Inc.
  • Bausch and Lomb Inc.
  • Cigna
  • Visine
  • Clear Eyes
  • Alcon
  • Viva Opti-Free
  • Bausch and Lomb
  • Novartis AG
  • Systane
  • Rite Aid
  • Allergan, Inc.
  • Staples
  • Similasan Corporation

Strategies And Objectives Of Major Companies:

  • Aerie Pharmaceuticals, Inc., an ophthalmic drug manufacturer concentrating on the invention, advancement, and monetization of first-in-class therapies of patient populations with transparent glaucoma and other eye diseases, announced the release of Rhopressa in the United States in April 2018.
  • Santen Pharmaceutical Co., Ltd. and Ube Industries, Ltd. launched a new glaucoma and ocular hypertension treatment named EYBELIS Ophthalmic Solution 0.002 percent (Omidenepag Isopropyl; hereinafter, EYBELIS) in Japan in November 2018. The API in EYBELIS, omidenepag isopropyl, is the country’s first selective EP2 receptor agonist, as well as an ocular hypotensive operator with a novel mechanism of action.

What Our Report Provides And Why Our Offering Is Better:

This report offers historical data points and forecasts and revenue growth at a global, regional, and country level, and provides analysis, industry trends, and consumption pattern details for each region, major country, and segment from 2018 to 2028. The global market report includes industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and market share contribution by each regional and country market. In addition, the report offers industry analysis and competitive landscape, company financials, and impact analysis. The report includes a detailed view of the global market, along with changing dynamics and trends, scenarios, detailed market and regional segmentation, regional landscape, analysis and evaluation, major investments, product offerings, product launches, and details of historical, current, and projected revenues.

Detailed Segmentation In Our Report:

For the purpose of this report, global antiglaucoma eye drops market is segmented on the basis of product type, disease condition, and region:

Product Type Outlook (Revenue, USD Billion; 2018-2028)

  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others

Disease Condition Outlook (Revenue, USD Billion; 2018-2028)

  • Open-angle Glaucoma
  • Angle-closure Glaucoma
  • Normal-tension Glaucoma
  • Congenital Glaucoma
  • Others

Region Outlook (Revenue, USD Billion; 2018-2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Benelux
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    •  South Africa
    • Rest of Middle East & Africa

Some points on how the report benefits stakeholders:

  • The reports include historical (2018–2020) and forecast (2021–2028) data points, revenues, and CAGR in table, figure, and chart formats, with detailed and qualitative, supporting written information for each.
  • Revenue break-up is provided for each segment in these formats for global, regional, and for each country in the respective region for each year between 2018 and 2028.
  • The report contains insights regarding growth drivers, restraints, opportunities, trends, company profiles, strategic developments, expansion details, product launches, and various other aspects related to the market.
  • The report contains data and information on customers, competitors, vendors/distributors, and other players and in the global marketplace.
  • Market research analysis is vital for all crucial business strategies and can aid in numerous ways and to provide a clearer understanding about strategies being deployed by competitors, product launches, competitive analysis, technological advancements and various other factors that enhance sales of a firm or perhaps provide insights to focus on merger and acquisition as a strategy or enter into strategic agreements or joint ventures etc.
  • The report contains company profiles of the top companies operating in the market along with their respective revenue and operating segments, geographical reach, market footprint, headquarters, growth rates, recent developments, product /services, expansion strategies, investments in expansion, and more.

REQUEST SAMPLE REPORT

Get Free Sample Report

REQUEST SAMPLE REPORT

REQUEST FOR CUSTOMIZATION

Tailor-make Your Research

REQUEST CUSTOMIZATION

Key questions answered by the report